Information status: July 8, 2026. This article explains clinical-trial terminology. It does not indicate that any specific trial is currently recruiting, nor does it constitute enrollment advice or any promise of therapeutic effect.
Regenerative-medicine news often features terms like “world’s first,” “Phase I/II,” “conditional and time-limited approval,” and “jRCT registration.” If readers see only the headline, it is easy to conflate research, trials, approval, and commercial treatment. The glossary below helps you understand the basic information first.
What Is jRCT
jRCT is Japan’s clinical-research submission and public-disclosure system. You can search for information on clinical research and clinical trials conducted in Japan, including the trial number, disease, study status, medical institution, eligibility criteria, and intervention details. It is an important entry point for judging whether a study is genuinely registered, but registration itself does not mean efficacy has been proven.
What Phase I, II, and III Mean
- Phase I: usually focuses more on safety, tolerability, dose, or method of administration.
- Phase II: makes a preliminary assessment of efficacy and safety in a larger group of patients.
- Phase III: a larger-scale comparison, usually used to confirm efficacy and safety.
- Phase I/II: combines early-safety and preliminary-efficacy objectives within the same study design.
Regenerative-medicine, medical-device, or surgical studies sometimes cannot be mapped directly onto the drug-trial phases, so you need to look at the specific study design and endpoints.
How to Read Recruitment Status
“Recruiting” indicates that enrollment may be possible in theory, but it does not mean every patient can take part. You also need to consider the inclusion criteria, exclusion criteria, study sites, language communication, residency requirements, prior treatment, and follow-up capacity.
Inclusion Criteria and Exclusion Criteria
Inclusion criteria determine what kind of person may consider taking part; exclusion criteria determine which situations cannot take part. Common restrictions in regenerative medicine include disease stage, organ function, infection status, immunosuppression risk, prior treatment, tumor history, age, and physical condition.
Primary and Secondary Endpoints
The primary endpoint is the study’s most central measure — for example, safety events, functional improvement, imaging changes, or a specific rating scale. Secondary endpoints are supporting measures. When reading about a clinical trial, don’t just look at news that says it “succeeded”; look at whether what it actually reached was safety, feasibility, symptom improvement, or a long-term clinical outcome.
Adverse Events and Serious Adverse Events
Adverse events are not necessarily all caused by the treatment, but all of them need to be recorded and evaluated. Serious adverse events usually involve death, a life-threatening situation, hospitalization, disability, congenital abnormality, or another medically important event. Regenerative medicine in particular requires long-term observation.
Conditional and Time-Limited Approval
The PMDA has a conditional and time-limited approval system for regenerative medical products. It allows earlier entry into clinical use under certain conditions but requires that efficacy and safety continue to be confirmed afterward. This is not “no re-verification needed at all,” nor does it mean every patient can use it immediately.
Eight Questions to Ask During a Consultation
- Is this a clinical trial, an approved product, or self-funded (free) treatment?
- Is there a jRCT, UMIN, or ClinicalTrials.gov number?
- Is it currently still recruiting? Is it open to patients within Japan only, or can overseas patients also inquire?
- What is the primary endpoint: safety, symptoms, function, imaging, or survival?
- How long is the hospitalization, how long is the follow-up, and is long-term return to Japan required?
- Are there special risks such as immunosuppression, infection, tumor formation, or arrhythmia?
- Who bears the cost, and does it include examinations, cell preparation, surgery, and follow-up?
- If enrollment is not suitable, is there a standard treatment or another reasonable option?
This glossary serves as a foundational explainer for Tsubaki’s regenerative-medicine section; related clinical-trial articles can link back here so readers can understand the key concepts first.